Lonial, S., Yhim, H., Caruso, V., Jo, J., Jung, S., Koh, Y., Barth, P., Deheshi, S., Kalaitzaki, E., Kremer, B., Boyle, J., Jackson, N., Sun, W., Carreño, F., Mukhopadhyay, P., Opalinska, J., Dimopoulos, M. A. (2025). Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps7567